UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) yesterday submitted a regulatory application in the European Union for their investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD) under the proposed proprietary name Anoro. Theravance’s shares closed up 4.5% at $22.69 yesterday, while GSK advanced 0.5% to £13.81.
UMEC/VI is a combination of two investigational bronchodilator molecules - GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta(2) agonist (LABA), administered using the Ellipta inhaler.
Last month, GSK and Theravance announced the submission of a regulatory application in the USA for UMEC/VI, for patients with COPD (The Pharma Letter December 19, 2012). A Prescription Drug User Fee Act (PDUFA) goal date has been confirmed as May 12, 2013.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze